PHARMACEUTICAL IMPORT COMPLIANCE & TGA SUPPORT

The Australian sponsor remains responsible for the medicine after market entry.

Depending on the product, this can include maintaining the ARTG entry, managing relevant changes, overseeing overseas GMP compliance, monitoring product quality and safety, maintaining records and responding to product issues.

Maintain current GMP clearance for the relevant overseas sites and manufacturing steps, and ensure release-for-supply arrangements give the authorised person access to the information needed to assess each batch.

Quality agreements, batch documentation and traceability records should support that process throughout the product lifecycle.

HCPA can help review how these requirements work together across your imported medicine portfolio.

Where GMP clearance is required, the Australian sponsor needs appropriate evidence that the relevant overseas manufacturing sites meet acceptable GMP standards.

The clearance should cover the manufacturing activities performed for the Australian product.

The TGA advises sponsors to apply for renewal at least six months before the clearance expires, making expiry monitoring an important part of routine compliance.

Release for supply must be performed by an authorised person under the appropriate manufacturing authorisation.

An overseas manufacturer may perform the step where the relevant requirements are met. If an Australian sponsor performs release for supply itself, the appropriate TGA manufacturing licence is required.

Relevant information can include ARTG and marketing-authorisation details, GMP clearances, certificates of analysis, manufacturing and test records, stability information, deviations, approved specifications and supply-chain records.

The information available should allow the authorised person to determine whether the batch meets the requirements for supply.

Quality or GMP agreements help define which party is responsible for activities affecting product quality and compliance.

The TGA expects valid agreements to clearly allocate GMP-related responsibilities, particularly where activities are contracted across multiple organisations. 

Product codes, batch or lot numbers and expiry dates are core traceability information.

These details should connect with supply-chain records so affected products can be traced through warehouses, orders and customers if an issue or recall occurs.

Start by identifying the issue, affected products or manufacturing sites and the timeframe provided by the TGA.

Control any immediate risk, investigate the underlying cause and prepare corrective actions supported by appropriate evidence.

HCPA can help organise the investigation, corrective action plan and regulatory response.

Issues can arise where GMP evidence is no longer current or sufficient, the clearance scope does not cover the required manufacturing activities or sponsor obligations have not been maintained.

Resolving the issue may require updated GMP evidence, changes to the clearance scope or improvements to manufacturer and quality oversight.

Yes. Where sponsor responsibilities are not met, the TGA may take action affecting an active GMP clearance.

The appropriate response will depend on the issue, available evidence and any requirements raised by the TGA.

A corrective action plan should identify the compliance issue, underlying cause, immediate corrections, longer-term actions, responsibilities, completion dates and supporting evidence.

It should also explain how the business will reduce the risk of the same issue recurring.

No. Depending on the issue, the appropriate market action may involve return, removal or correction rather than destruction.

Certain problems, such as some labelling errors, may be capable of correction where permitted by the TGA.

Product identifiers, batch or lot numbers and expiry dates help identify affected stock, while supply-chain records show where those products were stored and supplied.

Reliable traceability allows affected medicines to be identified and managed more efficiently when a recall or correction is required.

A pharmaceutical compliance specialist can help assess the issue, determine what evidence or corrective work is required and coordinate the response.

HCPA can support GMP clearance issues, product traceability, recalls, remediation and preparation of the regulatory response.

Review the underlying systems and strengthen any weaknesses that contributed to the issue.

Depending on the problem, this may involve GMP clearance monitoring, manufacturer oversight, quality agreements, traceability, storage controls or documentation.